Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT SHAREHOLDING INCREASE PLAN BY THE CHAIRMAN OF THE BOARD

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company has been informed by Dr. Kang Xiaoqiang ("**Dr. Kang**"), the chairman of the Board, an executive Director, the chief executive officer and the general manager of the Company, that based on his recognition of the Company's value and his confidence in the future overall business development and growth potential of the Company, Dr. Kang plans to increase his shareholding by acquiring H shares of the Company (the "**H Shares**") in the open market using his own or his close associates' funds within approximately six months from the date of this announcement at a total consideration expected not to exceed HK$20 million (the "**Shareholding Increase Plan**"), subject to compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other applicable laws and regulations. Dr. Kang may acquire additional H Shares from time to time subject to market conditions and applicable regulatory requirements.

As at the date of this announcement, Dr. Kang was interested or deemed to be interested in an aggregate of 29,500,320 H Shares, representing approximately 14.92% of the issued H Shares, and approximately 14.83% of the total issued share capital of the Company.

Based on the information available to the Company and to the best knowledge and belief of the Directors, if the Shareholding Increase Plan is fully implemented, the Company will continue to maintain a sufficient public float of the issued H Shares.

The Board is of the view that the Shareholding Increase Plan reflects Dr. Kang's firm confidence in the value and long-term development prospects of the Company.

Shareholders and potential investors should note that the Shareholding Increase Plan may or may not be fully implemented due to the changes in the capital market and unforeseeable factors in the coming future. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, November 19, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.